Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 26Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 447Surgical Procedures, Operative 165Observation 152Drug Therapy 143Radiotherapy 142Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 79Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 67Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 62Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Acceptance and Commitment Therapy × Clear all
NCT03910296 2022-05-03

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Dana-Farber Cancer Institute

Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04636346 2020-12-17

COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF

University of California, San Francisco

Completed
129 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡